What are the disclosed terms of the BioNTech and DualityBio ADC licensing deal?
For the two-asset partnership announced on April 3, 2023, DualityBio disclosed US$170 million upfront, more than US$1.5 billion in potential milestones and single-digit to double-digit tiered royalties. [1]
That agreement covered DB-1303 and DB-1311, with BioNTech holding commercial rights outside Mainland China, Hong Kong and Macau. [1]
BioNTech’s 2023 annual report subsequently included the August DB-1305 agreement and reported US$220 million in combined Duality upfront payments. [1]
Dated evidence
| Claim | Value | As of | Source and original quotation |
|---|---|---|---|
| April 2023 upfront | USD 170,000,000 for DB-1303 and DB-1311 together | 2023-04-03 | Primary source$170 million |
| April 2023 potential milestones | Over USD 1,500,000,000 | 2023-04-03 | Primary sourceover $1.5 billion |
| April 2023 royalty range | Single-digit to double-digit tiered royalties | 2023-04-03 | Primary sourcesingle-digit to double-digit |
| Assets and territory | DB-1303 and DB-1311; BioNTech rights outside Mainland China, Hong Kong and Macau | 2023-04-03 | Primary sourceDB-1303 and DB-1311 |
| 2023 combined upfront after third ADC | USD 220,000,000; includes DB-1305 agreement signed in August 2023 | 2023-12-31 | Primary source$220.0 million |
Not disclosed in the public documents
The checked public announcements and annual report do not disclose the exact royalty percentages at every tier or allocate all upfront amounts by individual asset. Document reviewed 2026-10-22
tiered royalties